SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|
| RELVAR ELLIPTA | 100,25 µg,µg | Inhalation powder · Inhalation use | 1 Inhaler | SAR 158.40 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
| RELVAR ELLIPTA 200/25 mcg inhalation powder | 200,25 µg,µg | Inhalation powder · Inhalation use | 1 Inhaler | SAR 158.40 | NCE · Prescription | Glaxo Saudi Arabia Ltd. | Valid |
Indications — CHI Daman Drug Formulary
ASTHMA; CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
EMA European Union — centrally authorised medicines
Relvar Ellipta GlaxoSmithKline Trading Services Limited · Authorised · authorised 13 Nov 2013 · ATC R03AK10
Therapeutic indication (EMA)
Asthma indication: Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate: patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists. patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist. COPD indication: Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 <70% predicted normal (post-bronchodilator) in patients with an exacerbation history despite bronchodilator therapy.
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|
| BREO ELLIPTA | 02408872 | 100 MCG / ACT; 25 MCG / ACT | POWDER · INHALATION | GLAXOSMITHKLINE INC |
| BREO ELLIPTA | 02444186 | 25 MCG / ACT; 200 MCG / ACT | POWDER · INHALATION | GLAXOSMITHKLINE INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|
| US NADAC | FLUTICASONE-VILANTEROL 100-25 | $3.8971 | per EA | 23 Sep 2026 |
| US NADAC | FLUTICASONE-VILANTEROL 200-25 | $3.91371 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Fluticasone furoate 184micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler | £29.50 | 30 dose | 1 Oct 2026 |
| NHS Drug Tariff | Fluticasone furoate 92micrograms/dose / Vilanterol 22micrograms/dose dry powder inhaler | £22.00 | 30 dose | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
WHO WHO Model List of Essential Medicines (2025)
- 25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease · core
Therapeutic equivalent to budesonide + formoterol for Asthma
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.